The National Institute of Allergy and Infectious Diseases’ (NIAID) trial of the antiviral remdesivir for the treatment of COVID-19 met its primary endpoint, Gilead Sciences Inc. said in a statement on Wednesday. The company also published its results from the Phase-3 trial with key takeaways found below.
Tonight, risk-on with the expectation of economic recovery from the new Corona.
,Crude oil stock prices are both skyrocketing.
Continue to buy NZDCHF.
Currently, the power balance in 15 minutes is
CAD ＞ EUR ＞ NZD ＞ AUD ＞ USD ＞ CHF ＞ JPY ＞ GBP
